Net Product Sales PerformanceNet product sales increased 16% to $1,337 million and reflect strong volume growth in the U.S., Europe and Japan. U.S. and international net product sales of $772 million and $565 million increased 15 percent and 19 percent, respectively.
- REVLIMID sales for the second quarter increased 17 percent to $934 million and were driven by overall market share gains, increased duration of therapy and geographic expansion. U.S. sales of $537 million and international sales of $397 million increased 17 percent and 18 percent, respectively.
- ABRAXANE sales for the second quarter were $110 million, a 16 percent increase. U.S. sales of $87 million and international sales of $23 million increased 20 percent and 3 percent, respectively.
- VIDAZA ® second quarter sales increased 24 percent to $201 million. U.S. sales increased 12 percent to $82 million. International sales increased 35 percent to $119 million, driven by underlying patient demand in Europe and Japan.
- THALOMID ® sales were $76 million in the second quarter, representing a 13 percent decrease.